ASGCT 2026: Gene Therapy Manufacturing Advances to Watch

Key Takeaways

• ASGCT 2026 will be held May 11-15 in Boston, MA.
• No specific manufacturing-focused presentations are highlighted in initial announcements, but related insights may emerge.
• The primary focus is on clinical and biological aspects of gene and cell therapies.

The American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2026 is scheduled to take place May 11-15, 2026, in Boston, MA. While the initial announcements do not highlight specific presentations focused on gene therapy manufacturing, attendees may glean relevant insights from clinical data and company presentations. The meeting will feature oral presentations, posters, and symposia covering the latest advancements in gene and cell therapies.

The ASGCT Annual Meeting is a key event for researchers, clinicians, and industry professionals involved in gene and cell therapy. It provides a platform to share the latest scientific findings, technological advancements, and clinical trial results. With the field rapidly evolving, the ASGCT meeting is crucial for staying abreast of the newest developments and fostering collaborations.

Potential Manufacturing Relevance

Although dedicated manufacturing sessions are not yet apparent, process development and scalability insights could surface during clinical data presentations. Companies like Circio Holding, MiNK Therapeutics, and Encoded Therapeutics are scheduled to present data that may indirectly address manufacturing considerations. Attendees should also monitor poster sessions and exhibitor booths for relevant technologies and services.

IntelligenceRegulatory Impact▾

FDA set GMP, data-integrity, and post-approval change expectations for sterile and biologics manufacturing in the Americas. Regulatory relevance reads medium for manufacturing. Track inspection trends, Annex 1 alignment, and submission pathways for continuous manufacturing.

Companies to Watch

• Circio Holding: The circVec (AAV-circVec 4.0) gene expression platform may offer insights into efficient gene expression. Preclinical data showed up to 50x enhanced gene expression in the eye and ~40x in the heart.
• MiNK Therapeutics: The agenT-797 allogeneic invariant natural killer T (allo-iNKT) cell therapy could provide learnings on cell therapy manufacturing. A poster presentation will detail the therapy's adaptive immune modulation in cancer and acute respiratory distress syndrome (ARDS). Terese C. Hammond, MD, Program Director of Pulmonary and Critical Care at Kaweah Health and Head of Inflammatory and Pulmonary Diseases at MiNK, will present the poster.
• Encoded Therapeutics: Clinical data on ETX101, an AAV9-based gene regulation therapy for *SCN1A*-positive Dravet syndrome, will be presented at a Presidential Symposium. This data may inform scalable AAV9-based gene regulation therapy.
• Calidi Biotherapeutics: A speaker presentation on May 14, 2026, will highlight the RedTail platform's ability to deliver therapies.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low on capacity and tech-transfer positioning. Benchmark which CDMOs, equipment vendors, and sponsors adopt continuous and isolator platforms first. Supplier hub and pipeline links below connect to named partners.

Market & Investor Implications

Presentations at ASGCT 2026 can influence market sentiment and investor decisions. Positive clinical data readouts, particularly those demonstrating improved efficacy or safety, can boost company stock prices. Advances in gene therapy manufacturing technologies may also attract investment in companies developing innovative solutions for scalability and cost-effectiveness.

IntelligenceMarket Signals▾

Commercial pull is medium for manufacturing capacity, outsourcing, and supply resilience. Investment relevance is low — watch capex, licensing, and regional hub expansion.

What to Watch Next

The full ASGCT program, expected in mid-April, will provide a more detailed view of the presentations and sessions. Keep an eye out for late-breaking abstracts and additional manufacturing-focused content as the meeting approaches.

Frequently Asked Questions

• When and where is ASGCT 2026 being held?

  ASGCT 2026 will take place May 11-15, 2026, in Boston, MA.

• Will there be presentations specifically about gene therapy manufacturing?

  While no dedicated manufacturing sessions are currently announced, related insights may emerge from clinical data presentations and exhibitor showcases.

• Which companies should I watch at ASGCT 2026?

  Keep an eye on Circio Holding, MiNK Therapeutics, Encoded Therapeutics, and Calidi Biotherapeutics, among others presenting potentially relevant data.

• When will the full ASGCT program be available?

  The full program with poster and session details is expected in mid-April 2026.

References

• Circio Holding ASGCT Announcement
• FirstWord Pharma ASGCT Preview
• MiNK Therapeutics ASGCT Presentation Details
• MiNK Therapeutics Abstract Announcement
• Encoded Therapeutics ASGCT Symposium Announcement
• Calidi Biotherapeutics ASGCT Speaker Presentation

Related coverage

• $2M Gene Therapy Cures Need a Financing Model
• Gene Therapy FDA Approval for Rare Disease: Updated List and Analysis
• Exclusive: FDA issues industry-friendly gene therapy guidance: What BD teams need to know